225 related articles for article (PubMed ID: 26735889)
21. Integration of somatic mutation, expression and functional data reveals potential driver genes predictive of breast cancer survival.
Suo C; Hrydziuszko O; Lee D; Pramana S; Saputra D; Joshi H; Calza S; Pawitan Y
Bioinformatics; 2015 Aug; 31(16):2607-13. PubMed ID: 25810432
[TBL] [Abstract][Full Text] [Related]
22. Integrated multi-omics analysis of genomics, epigenomics, and transcriptomics in ovarian carcinoma.
Zheng M; Hu Y; Gou R; Wang J; Nie X; Li X; Liu Q; Liu J; Lin B
Aging (Albany NY); 2019 Jun; 11(12):4198-4215. PubMed ID: 31257224
[TBL] [Abstract][Full Text] [Related]
23. Subtype-specific signaling pathways and genomic aberrations associated with prognosis of glioblastoma.
Park AK; Kim P; Ballester LY; Esquenazi Y; Zhao Z
Neuro Oncol; 2019 Jan; 21(1):59-70. PubMed ID: 30053126
[TBL] [Abstract][Full Text] [Related]
24. Identification of Hub Genes in High-Grade Serous Ovarian Cancer Using Weighted Gene Co-Expression Network Analysis.
Wu M; Sun Y; Wu J; Liu G
Med Sci Monit; 2020 Mar; 26():e922107. PubMed ID: 32180586
[TBL] [Abstract][Full Text] [Related]
25. Integrative network analysis for survival-associated gene-gene interactions across multiple genomic profiles in ovarian cancer.
Jeong HH; Leem S; Wee K; Sohn KA
J Ovarian Res; 2015 Jul; 8():42. PubMed ID: 26138921
[TBL] [Abstract][Full Text] [Related]
26. Genome-wide DNA copy number profiling and bioinformatics analysis of ovarian cancer reveals key genes and pathways associated with distinct invasive/migratory capabilities.
Liu G; Ruan G; Huang M; Chen L; Sun P
Aging (Albany NY); 2020 Jan; 12(1):178-192. PubMed ID: 31895688
[TBL] [Abstract][Full Text] [Related]
27. Integrated miRNA-mRNA Expression Profiles Revealing Key Molecules in Ovarian Cancer Based on Bioinformatics Analysis.
Li C; Hong Z; Ou M; Zhu X; Zhang L; Yang X
Biomed Res Int; 2021; 2021():6673655. PubMed ID: 34734085
[TBL] [Abstract][Full Text] [Related]
28. Integrated analysis of recurrent properties of cancer genes to identify novel drivers.
D'Antonio M; Ciccarelli FD
Genome Biol; 2013 May; 14(5):R52. PubMed ID: 23718799
[TBL] [Abstract][Full Text] [Related]
29. Stroma-associated master regulators of molecular subtypes predict patient prognosis in ovarian cancer.
Zhang S; Jing Y; Zhang M; Zhang Z; Ma P; Peng H; Shi K; Gao WQ; Zhuang G
Sci Rep; 2015 Nov; 5():16066. PubMed ID: 26530441
[TBL] [Abstract][Full Text] [Related]
30. Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities.
Cheasley D; Nigam A; Zethoven M; Hunter S; Etemadmoghadam D; Semple T; Allan P; Carey MS; Fernandez ML; Dawson A; Köbel M; Huntsman DG; Le Page C; Mes-Masson AM; Provencher D; Hacker N; Gao Y; Bowtell D; deFazio A; Gorringe KL; Campbell IG
J Pathol; 2021 Jan; 253(1):41-54. PubMed ID: 32901952
[TBL] [Abstract][Full Text] [Related]
31. Competing endogenous RNA network analysis identifies critical genes among the different breast cancer subtypes.
Chen J; Xu J; Li Y; Zhang J; Chen H; Lu J; Wang Z; Zhao X; Xu K; Li Y; Li X; Zhang Y
Oncotarget; 2017 Feb; 8(6):10171-10184. PubMed ID: 28052038
[TBL] [Abstract][Full Text] [Related]
32. Gene-microRNA network module analysis for ovarian cancer.
Zhang S; Ng MK
BMC Syst Biol; 2016 Dec; 10(Suppl 4):117. PubMed ID: 28155675
[TBL] [Abstract][Full Text] [Related]
33. The Integrated Analyses of Driver Genes Identify Key Biomarkers in Thyroid Cancer.
Xu Q; Song A; Xie Q
Technol Cancer Res Treat; 2020; 19():1533033820940440. PubMed ID: 32812852
[TBL] [Abstract][Full Text] [Related]
34. Identification of Novel Breast Cancer Subtype-Specific Biomarkers by Integrating Genomics Analysis of DNA Copy Number Aberrations and miRNA-mRNA Dual Expression Profiling.
Li D; Xia H; Li ZY; Hua L; Li L
Biomed Res Int; 2015; 2015():746970. PubMed ID: 25961039
[TBL] [Abstract][Full Text] [Related]
35. An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer.
Bild AH; Parker JS; Gustafson AM; Acharya CR; Hoadley KA; Anders C; Marcom PK; Carey LA; Potti A; Nevins JR; Perou CM
Breast Cancer Res; 2009; 11(4):R55. PubMed ID: 19638211
[TBL] [Abstract][Full Text] [Related]
36. A pan-kidney cancer study identifies subtype specific perturbations on pathways with potential drivers in renal cell carcinoma.
Zhan X; Liu Y; Yu CY; Wang TF; Zhang J; Ni D; Huang K
BMC Med Genomics; 2020 Dec; 13(Suppl 11):190. PubMed ID: 33371886
[TBL] [Abstract][Full Text] [Related]
37. Identification of an energy metabolism‑related gene signature in ovarian cancer prognosis.
Wang L; Li X
Oncol Rep; 2020 Jun; 43(6):1755-1770. PubMed ID: 32186777
[TBL] [Abstract][Full Text] [Related]
38. Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer.
Yang D; He Y; Wu B; Deng Y; Wang N; Li M; Liu Y
J Ovarian Res; 2020 Jan; 13(1):10. PubMed ID: 31987036
[TBL] [Abstract][Full Text] [Related]
39. A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes.
Dutta B; Pusztai L; Qi Y; André F; Lazar V; Bianchini G; Ueno N; Agarwal R; Wang B; Shiang CY; Hortobagyi GN; Mills GB; Symmans WF; Balázsi G
Br J Cancer; 2012 Mar; 106(6):1107-16. PubMed ID: 22343619
[TBL] [Abstract][Full Text] [Related]
40. Integrating genomic, epigenomic, and transcriptomic features reveals modular signatures underlying poor prognosis in ovarian cancer.
Zhang W; Liu Y; Sun N; Wang D; Boyd-Kirkup J; Dou X; Han JD
Cell Rep; 2013 Aug; 4(3):542-53. PubMed ID: 23933257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
